Pharma & Biotech Global Week in Review 25 May 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

District Court Delaware grants TRO against Mylan’s generic Amrix, after finding patents invalid: In Re Cyclobenzaprine Hyldrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

The role of IP in global health (PatentlyBIOtech)

SPC Blog: Resources site updated (The SPC Blog)

WHO needs another year to solve differences on fake medicines, committee decides (IP Watch)

Workplan of WHO Group on Neglected Diseases R&D Shows Timeline (IP Watch)

Letter to the 129th WHO Executive Board on conflicts of interest, WHO reform and the future of financing (KEI)

Brazil’s role and intention during pandemics (IP tango)

EU: Short summary of the Medeva/Georgetown CJEU hearing (The SPC Blog)

Spain: What do court-appointed experts have in common with Caesar’s wife? (Kluwer Patent Blog)

USPTO statement at WIPO side event on Medicines Patent Pool (Knowledge Ecology International)

US: To implement health reform orphan drug exclusion, HRSA issues first-ever proposed regulation on 340B drug discount program (FDA Law Blog)

US: FDA officials hint at provisions of biosimilar guidances (Patent Docs)

US: Huffington Post: Data Exclusivity: Getting the balance right (PatentlyBIOtech)

US: Report gauges economic impact of Human Genome Project (Patent Docs)

US: Chairman Bernanke’s speech on government R&D spending policy and economic development (PatentlyBIOtech)

 

Products

Actos (Pioglitazone) – US: Breckenridge, Synthon settle Actos patent suit with Takeda (Patent Docs)

Alphagan (Brimonidine) – US: CAFC: In re Brimonidine Patent Litigation: Reviewing nonobviousness determinations (Patently-O) (IPBiz)

Amrix (Cyclobenzaprine) – US: District Court Delaware grants TRO against Mylan’s generic Amrix, after finding patents invalid: In Re Cyclobenzaprine Hyldrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog) (Patent Docs)

AndroGel (Testosterone) – US: Abbott Products files patent infringement complaint against Teva following Para IV certification filing (Patent Docs)

Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against Dr Reddy’s in response to Para IV certification (Patent Docs)

Concerta (Methylphenidate) – US: Alza files patent infringement complaint against Impax in response to Para IV filing (Patent Docs)

Coreg (Carvedilol) – US: Flamel Technologies files patent infringement complaint against Lupin in response to Para IV challenge (Patent Docs)

Crestor (Rosuvastatin) – It’s all in the definition – ‘drug’ or ‘pharmaceutical item’ (IP Whiteboard)

Intuniv (Guanfacine) – US: Shire files patent infringement suit against Sandoz over ANDA filing (Patent Docs)

K-DUR (Potassium chloride) – US: A flurry of amicus briefs filed in the K-DUR patent settlement appeal seek a reversal of a New Jersey District Court decision (FDA Law Blog)

Latisse (PGF) – US: CAFC tackles UCL § 17204 in Allergan v Athena Cosmetics (IPBiz)

NuvaRing (Etonogestrel, Ethinyl estradiol) – US: ALJ Luckern grants-in-part motion to compel in Certain Vaginal Ring Birth Control Devices (337-TA-768) (ITC 337 Law Blog)

Nuvigil (Armodafinil) – US: Cephalon drops Nuvigil suit against Teva (Patent Docs)

Opana (Oxymorphone) – US: Federal Circuit: Guidance on obviousness for pharmaceutical formulations and its supervisory powers over USPTO: In re Kao (Patent Docs)

Ovide (Malathion) – US: Taro Pharmaceuticals files patent infringement suit against Suven Life Sciences in response to Para IV certification (Patent Docs)

Prevacid SoluTab (Lansoprazole) – US: Takeda files patent infringement complaint in response to Para IV challenge (Patent Docs)

Renvela (Sevelamer) – US: Genzyme files patent infringement complaint against Endo Pharmaceuticals in response to Para IV certification (Patent Docs)

Seroquel (Quetiapine) – US: AstraZeneca files separate patent infringement suits against Osmotica and Mylan following Para IV certification as part of Osmotica’s ANDA filing (Patent Docs)

Viagra (Sildenafil) – Switzerland: ViaGuara vodka infringes on famous VIAGRA brand (Class 46)

Xyrem (Sodium Oxybate) – US: Jazz Pharmaceuticals files patent infringement suit against Roxane following Para IV certification filing (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: